Study on Two Ayurvedic Basti Patterns for Lumbar Spondylosis

Randomized Comparative Clinical study of Chaturbhadra Kalpa Basti and Kala Basti with Pancha Prasrutika Basti as Niruha in the management of Katigraha w.s.r. to Lumbar spondylosis - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/104187

Enrollment

Registered

2026-02-18

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M478- Other spondylosis

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases of Katigraha. Patients presenting with classical clinical features of Katigraha. Subjects of either gender between age group of 18-60 yr. Subjects fit for Niruha and Anuvasana Basti karma. Patients willing to follow up. Patients willing to give written informed consent

Exclusion criteria

Exclusion criteria: Patients who are contraindicated for Basti. Pregnancy and lactating women Bowel and Urine incontinence Post-surgical backache Patients suffering from Spondylolisthesis, Spina bifida, Tuberculosis of spine, Ankylosing spondylitis, spinal canal stenosis, malignancies, and any other metabolic and systemic disorders Patients participating in any other clinical study

Design outcomes

Primary

Measure	Time frame
Relief in symptoms such as Stambha (stiffness), Shoola (pain), and improvement in walking capacity is expectedTimepoint: GROUP A: DAY 0 (Baseline) DAY 5 (Between Treatment) DAY 9 (After Treatment) DAY 24 (Post-Treatment Follow-Up) GROUP B: DAY 0 (Baseline) DAY 6 (Between Treatment) DAY 13 (After Treatment) DAY 36 (Post-Treatment Follow-up)	—

Secondary

Measure	Time frame
Standardization parameters confirming batch-to-batch consistency Absence of adverse events in participants post administration Stability data over a defined storage period (3-6 months) under controlled conditions, including microbial and physical stability. Participant-recorded scores on ease of use and convenience via feedback form. Requirement of assistance for administration. Physician-reported preferences regarding safety, ease of administration, procedural hygiene, and patient acceptability. Timepoint: GROUP A: DAY 0 (Baseline) DAY 5 (Between Treatment) DAY 9 (After Treatment) DAY 24 (Post-Treatment Follow-Up) GROUP B: DAY 0 (Baseline) DAY 6 (Between Treatment) DAY 13 (After Treatment) DAY 36 (Post-Treatment Follow-up)	—

Measure

Time frame

Standardization parameters confirming batch-to-batch consistency Absence of adverse events in participants post administration Stability data over a defined storage period (3-6 months) under controlled conditions, including microbial and physical stability. Participant-recorded scores on ease of use and convenience via feedback form. Requirement of assistance for administration. Physician-reported preferences regarding safety, ease of administration, procedural hygiene, and patient acceptability. Timepoint: GROUP A: DAY 0 (Baseline) DAY 5 (Between Treatment) DAY 9 (After Treatment) DAY 24 (Post-Treatment Follow-Up) GROUP B: DAY 0 (Baseline) DAY 6 (Between Treatment) DAY 13 (After Treatment) DAY 36 (Post-Treatment Follow-up)

—

Countries

India

Contacts

Public ContactDr Parul

Parul Institute of Ayurved and Research,Vadodara

Jigicharel504@gmail.com9428122325

Outcome results